• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国心脏再同步治疗除颤器植入术后院内不良结局和费用利用的频率。

Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.

机构信息

Internal Medicine Department, Saint Peter s University Hospital, New Brunswick, New Jersey.

Cardiovascular Disease, Tulane University School of Medicine, New Orleans, Louisiana.

出版信息

J Cardiovasc Electrophysiol. 2018 Oct;29(10):1425-1435. doi: 10.1111/jce.13701. Epub 2018 Sep 6.

DOI:10.1111/jce.13701
PMID:30016005
Abstract

BACKGROUND

The utilization of cardiac resynchronization therapy defibrillator (CRT-D) has increased significantly, since its initial approval for use in selected patients with heart failure. Limited data exist as for current trends in implant-related in-hospital complications and cost utilization. The aim of our study was to examine in-hospital complication rates associated with CRT-D and their trends over the last decade.

METHODS AND RESULTS

Using the Nationwide Inpatient Sample, we estimated 378 248 CRT-D procedures from 2003 to 2012. We investigated common complications, including mechanical, cardiovascular, pericardial complications (hemopericardium, cardiac tamponade, or pericardiocentesis), pneumothorax, stroke, vascular complications (consisting of hemorrhage/hematoma, incidents requiring surgical repair, and accidental arterial puncture), and in-hospital deaths described with CRT-D, defining them by the validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code. Mechanical complications (5.9%) were the commonest, followed by cardiovascular (3.6%), respiratory failure (2.4%), and pneumothorax (1.5%). Age (≥65 years), female gender (OR, 95% CI; P value) (1.08, 1.03-1.13; 0.001), and the Charlson score ≥3 (1.52, 1.45-1.60; <0.001) were significantly associated with increased mortality/complications.

CONCLUSIONS

The overall complication rate in patients undergoing CRT-D has been increasing in the last decade. Age (≥65), female sex, and the Charlson score ≥3 were associated with higher complications. In patients who underwent CRT-D implantation, postoperative complications were associated with significant increases in cost.

摘要

背景

自最初批准将心脏再同步治疗除颤器(CRT-D)用于有选择的心力衰竭患者以来,其使用率显著增加。目前关于植入相关院内并发症和成本利用的趋势数据有限。我们研究的目的是检查与 CRT-D 相关的院内并发症发生率及其在过去十年中的趋势。

方法和结果

使用全国住院患者样本,我们估计 2003 年至 2012 年期间有 378248 例 CRT-D 手术。我们调查了常见并发症,包括机械、心血管、心包并发症(血心包、心脏压塞或心包穿刺)、气胸、中风、血管并发症(包括出血/血肿、需要手术修复的事件和意外动脉穿刺)和 CRT-D 相关的院内死亡,通过验证的国际疾病分类,第九修订版,临床修正诊断代码来定义它们。机械并发症(5.9%)最常见,其次是心血管并发症(3.6%)、呼吸衰竭(2.4%)和气胸(1.5%)。年龄(≥65 岁)、女性性别(OR,95%CI;P 值)(1.08,1.03-1.13;0.001)和 Charlson 评分≥3(1.52,1.45-1.60;<0.001)与死亡率/并发症增加显著相关。

结论

过去十年中,接受 CRT-D 治疗的患者的总体并发症发生率一直在增加。年龄(≥65 岁)、女性性别和 Charlson 评分≥3 与更高的并发症相关。在接受 CRT-D 植入的患者中,术后并发症与成本的显著增加相关。

相似文献

1
Frequency of in-hospital adverse outcomes and cost utilization associated with cardiac resynchronization therapy defibrillator implantation in the United States.美国心脏再同步治疗除颤器植入术后院内不良结局和费用利用的频率。
J Cardiovasc Electrophysiol. 2018 Oct;29(10):1425-1435. doi: 10.1111/jce.13701. Epub 2018 Sep 6.
2
Facility-Level Variation and Clinical Outcomes in Use of Cardiac Resynchronization Therapy With and Without an Implantable Cardioverter-Defibrillator.使用和不使用植入式心脏复律除颤器的心脏再同步治疗中的机构层面差异与临床结局
Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e004763. doi: 10.1161/CIRCOUTCOMES.118.004763.
3
Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013.心脏再同步治疗的应用和院内并发症:2003 年至 2013 年美国的趋势。
Eur Heart J. 2017 Jul 14;38(27):2122-2128. doi: 10.1093/eurheartj/ehx100.
4
Cardiac Resynchronization Therapy: US Trends and Disparities in Utilization and Outcomes.心脏再同步治疗:美国的使用趋势及利用情况与治疗结果的差异
Circ Arrhythm Electrophysiol. 2016 Mar;9(3):e003108. doi: 10.1161/CIRCEP.115.003108.
5
Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.心力衰竭合并心房颤动患者心脏再同步治疗的比较效果:来自国家心血管数据注册中心植入式心律转复除颤器注册研究的结果
Circ Heart Fail. 2016 Jun;9(6). doi: 10.1161/CIRCHEARTFAILURE.115.002324.
6
Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.心脏植入式电子设备置换术后第一年内发生铅损伤的发生率及相关费用。
J Am Heart Assoc. 2016 Feb 12;5(2):e002813. doi: 10.1161/JAHA.115.002813.
7
The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.植入式心脏再同步治疗除颤器中电池寿命的经济影响:医院和医疗保健系统的观点。
Europace. 2017 Aug 1;19(8):1349-1356. doi: 10.1093/europace/euw176.
8
Impact of community wealth on use of cardiac-resynchronization therapy with defibrillators for heart failure patients.社区财富对心力衰竭患者使用心脏再同步除颤器治疗的影响。
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):798-807. doi: 10.1161/CIRCOUTCOMES.112.965509. Epub 2012 Oct 23.
9
PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.PR 间期可预测非左束支传导阻滞患者的临床反应:多中心自动除颤器植入试验-心脏再同步治疗亚研究。
Circ Arrhythm Electrophysiol. 2014 Aug;7(4):645-51. doi: 10.1161/CIRCEP.113.001299. Epub 2014 Jun 24.
10
Risk factors and the effect of cardiac resynchronization therapy on cardiac and non-cardiac mortality in MADIT-CRT.MADIT-CRT 中的心脏再同步治疗的心脏和非心脏死亡率的风险因素及影响。
Europace. 2015 Dec;17(12):1816-22. doi: 10.1093/europace/euv201. Epub 2015 Jun 11.

引用本文的文献

1
Negative effects of COVID-19 on the implantation rate of cardiac resynchronization therapy with defibrillator device.新冠病毒病对植入式心脏复律除颤器心脏再同步治疗植入率的负面影响。
J Arrhythm. 2024 Jan 16;40(2):237-246. doi: 10.1002/joa3.12994. eCollection 2024 Apr.
2
Independent and Joint Association of Statin Therapy with Adverse Outcomes in Heart Failure Patients with Atrial Fibrillation Treated with Cardiac Resynchronization Therapy.他汀类药物治疗与接受心脏再同步治疗的心力衰竭合并心房颤动患者不良结局的独立及联合关联
J Inflamm Res. 2022 Dec 9;15:6645-6656. doi: 10.2147/JIR.S390127. eCollection 2022.
3
Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011-2015: Insights from the National Cardiovascular Data Registry.
2011 - 2015年美国植入式心脏复律除颤器心脏再同步治疗患者的时间趋势和长期预后:来自国家心血管数据注册库的见解
Heart Rhythm O2. 2022 Apr 2;3(4):405-414. doi: 10.1016/j.hroo.2022.03.004. eCollection 2022 Aug.
4
Impact of Comorbidity Burden on Cardiac Implantable Electronic Devices Outcomes.合并症负担对心脏植入式电子设备预后的影响。
Clin Med Insights Cardiol. 2022 Jun 27;16:11795468221108212. doi: 10.1177/11795468221108212. eCollection 2022.
5
Device infections related to cardiac resynchronization therapy in clinical practice-An analysis of its prevalence, risk factors and routine surveillance at a single center university hospital.临床中心脏再同步治疗相关器械感染:单中心大学医院的流行率、危险因素和常规监测分析。
Clin Cardiol. 2021 Jun;44(6):739-747. doi: 10.1002/clc.23620. Epub 2021 May 25.